AMBROSE Cell Therapy’s Cycle of Care

The CEO of AMBROSE Cell Therapy, Matthew “Matt” Feshbach became interested in the possibility of stem cell therapies in 2009. Matthew Feshbach was able to start the company he had envisioned only after the Right to Try Act was passed in 2018, as it aligned to the technology, processes, and patient selection criteria he considered would most effectively serve the unmet need of no-option patients. The goal of the company is to mitigate symptoms and improve the functioning and quality of life in persons with chronic degenerative diseases through adult stem cell therapy.

AMBROSE Cell Therapy offers a personalized approach to each patient's care cycle, from the initial consultation with their MD patient consultant to the cell therapy treatment and advised aftercare programs. AMBROSE procedure protocols include tissue harvesting, direct injections (where indicated), and preparation and distribution of autologous adipose-derived stem and regenerative cells (ADRCs). Each tailored treatment plan is established with the specific needs of the patient in mind. For instance, certain illnesses, such as those affecting the lungs, kidney, liver, or brain, are best treated via intravenous injection. By contrast, a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and psoriatic arthritis, as well as neuropathies, require localized injections.

To help boost the success rate of cell therapy, AMBROSE also recommends patients reduce excess stress and inflammation through prudent food choices, exercise, a supportive family and social environment, and lifestyle changes. This is because stress, inflammation, dysregulation of the immune system, and both acute and chronic disease have been scientifically demonstrated to be significantly connected.